Ngm Biopharmaceuticals Inc
NGM
Get informed when a big investor buys or sells
+ FollowMarket Cap$128.53M
Close$
$0.61
60.2% downside
Current Fair Value
60.2% downsideOvervalued by 60.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $128.53 Million |
|---|---|
| Enterprise Value | $69.72 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.73 |
| Beta | 1.26 |
| Outstanding Shares | 82,803,000 |
Return
| Return on Equity | -94.07% |
|---|---|
| Return on Assets | -82.80% |
| Return on Invested Capital | -102.21% |
Valuation & Multiples
| P/E Ratio | -0.89 |
|---|---|
| PEG | 3.71 |
| Price to Sales | - |
| Price to Book Ratio | 1.54 |
| Enterprise Value to Revenue | 15.78 |
| Enterprise Value to EBIT | -0.46 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ngm Biopharmaceuticals Inc
CEO: David Woodhouse